Vanderbilt-Ingram was among the first in the nation to establish outpatient protocols for another personalized immunotherapy, CAR-T.

Study supports the potential benefits of screening patients for CHIP before they undergo cancer treatment so they can be more closely monitored for heart complications.

The findings could lead to new treatments for blood cancers, which kill an estimated 23,540 people in the United States every year.

Lung cancer is the leading cause of cancer death in the United States, with incidence higher in veterans compared to the civilian population.

In addition to her research, Dr. Means mentored dozens of undergraduate, graduate and postdoctoral students, research staff and faculty.

Vanderbilt-Ingram Cancer Center accrued the most patients nationwide for the clinical trial for P-BCMA-ALLO1 – a chimeric antigen receptor T cell therapy (CAR-T) derived from healthy donors’ white blood cells.

Established in 1958, ASH is the world’s largest professional organization for clinicians and scientists who study blood diseases.